160 likes | 268 Views
Fishing in Canada may be hazardous to your health: A 55 yo man with nausea. Christie Seibert, MD September 27, 2006. History of Present Illness. 55yo man fishing in Canada, snagged his 3 rd finger on a fishing hook. Initially only painful.
E N D
Fishing in Canada may be hazardous to your health: A 55 yo man with nausea Christie Seibert, MD September 27, 2006
History of Present Illness • 55yo man fishing in Canada, snagged his 3rd finger on a fishing hook. Initially only painful. • One week later, started getting red and swollen. • Returned to Madison, went to ER when it started draining pus and looking “angry”.
Other History • PMH • Diabetes (on glargine and asparte insulin, metformin and rosiglitazone. Last HbA1c was 7.5) • HTN(on lotensin) • Hyperlipidemia (on simvastatin) • GERD • SH: Married, home care worker for Hospice, triathlete, non-smoker, no Etoh • ROS: No F/C, malaise
Emergency Room • ER doc incised and drained a small abscess on pt’s 3rd finger. • Gave 2g IV Unasyn and 900mg IV Clinda • Wound cx: MRSA, sensitive to Clinda • Sent home w/ oral Augmentin and Clinda.
1st Followup Visit (4 d after ER) • Finger still swollen and very painful. Redness is markedly better. No F/C. • Blood sugars higher (160-180’s) than usual (120-130’s). • Antibiotics extended from planned 7 days to 10 days.
2nd Followup Visit (7d after ER) • Finger still painful and swollen, esp at PIP joint. Sig loss of ROM at PIP joint. • Blood sugars: some > 300. • Developing malaise, severe nausea and epigastric pain. • Xray: Sig DJD of PIP and DIP joints of the 3rd finger. Possible widening of the joint space at the PIP joint. No erosions or active osteo.
Physical Exam • Weight 207 (BMI 29) • BP 112/72 • Sclerae icteric, rest of HEENT WNL • CV, Lungs WNL • Liver edge not palpable, no ascites • Skin: no spider angiomatas or gynecomastia
Testing • MRI: Severe focal osteoarthritis of the third PIP joint. No findings of superimposed septic joint, abscess, osteomyelitis, or foreign body are seen. • Labs: • Alk Phos: 535 • ALT/AST: 401/110 • Total Bili: 5.0 Direct Bili: 3.1 • Nl CBC, lytes, BUN/Cr
Amoxacillin-Clavulanic Acid Hepatotoxicity • Learning Objectives • Recognize the possibility of hepatotoxicity from amox-clav acid • Know who might be at highest risk of this adverse reaction • Know how to manage amox-clav acid hepatotoxicity
Pharmacology 101 • Bacteria can produce penicillinases (like B-lactamase) to inhibit penicillin • To combat this, clavulanic acid is added. • Produced from Streptomyces organism • Has a B-lactam ring like penicillin • Acts as “suicide” non-competitive inhibitor, forms inactive complex with B-lactamase
Pharmacology 102 • In vivo spectrum of activity: Staph epi, Enterococci, Bacteroides, other anaerobes • Used in bite wounds, otitis media, sinusitis, lower resp tract and cutaneous infections • Clavulanic Acid (clavulanate) is combined • With Amox (Augmentin) • With Ticarcillin (Timentin)
Amoxacillin-Clavulanic Acid Hepatotoxicity • Rare adverse reaction (1-100/100,000) • Clavulanic acid thought to be culprit • Usually cholestatic picture • Idiosyncratic/not dose-dependent • Time to onset: average 25 days • Prognosis good, usually reversible • Resolution of jaundice by 1-8 weeks, complete recovery in 4-16 weeks
Possible Risk Factors • ? Risk in men (2:1 ratio) • ? Risk over age 60 • ? Risk in longer treatment (>10 days) • ? Risk if previous drug hepatotoxicity • Probably not related • Underlying liver disease • Co-medication with other hepatotoxic drugs
Resolution of Case • Possible hepatotoxic meds were stopped • Amox-clav acid • Rosiglitizone • Metformin • Simvistatin • Hep A, B, C testing negative • Abd ultrasound negative • LFTs peaked with TB at 6-7 range, then resolved over 3 weeks.
Bibliography • Zaidi SA. Hepatitis associated with Amoxacillin/Clavulanic Acid and/or Ciprofloxacin. Amer J Med Sci 2003; 325(1): 31-3. • Dowsett JF et al. Amoxicillin/Clavulanic Acid Induced Intrahepatic Cholestatis. Dig Dis Sci 1989;34(8):1290-3. • Gresser U. Amoxacillin-clavulanic acid therapy may be associated with severe side effects—a review of the literature. Eur J Med Res 2001; 6(4): 139-49.